UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
18.87
+0.77 (4.25%)
At close: Sep 18, 2025, 4:00 PM EDT
18.40
-0.47 (-2.49%)
After-hours: Sep 18, 2025, 7:17 PM EDT
UroGen Pharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover UroGen Pharma stock have a consensus rating of "Strong Buy" and an average price target of $28.5, which forecasts a 51.03% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $47.
Price Target: $28.5 (+51.03%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 19, 2025.
Analyst Ratings
The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Hold | 1 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $36 | Buy | Initiates | $36 | +90.78% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +111.98% | Aug 11, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +32.49% | Aug 7, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +32.49% | Aug 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +164.97% | Jul 8, 2025 |
Financial Forecast
Revenue This Year
126.22M
from 90.40M
Increased by 39.63%
Revenue Next Year
266.94M
from 126.22M
Increased by 111.49%
EPS This Year
-2.88
from -2.96
EPS Next Year
-0.77
from -2.88
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 143.3M | 411.1M | |||
| Avg | 126.2M | 266.9M | |||
| Low | 103.9M | 220.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.6% | 225.7% | |||
| Avg | 39.6% | 111.5% | |||
| Low | 14.9% | 74.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.97 | 2.14 | |||
| Avg | -2.88 | -0.77 | |||
| Low | -3.30 | -3.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.